NIKKEI 225
30,654.47 -583.47 (-1.87%) HANG SENG
17,159.77 -171.45 (-0.99%) CRUDE OIL
89.17 -0.06 (-0.07%) GOLD FUTURES
1,837.00 -4.50 (-0.24%) DOW
33,002.38 -430.97 (-1.29%) Bitcoin GBP
22,672.22 -173.13 (-0.76%)
Novozymes A/S (NVZMF)
| Previous close | 40.65 |
| Open | 39.77 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 39.77 - 39.77 |
| 52-week range | 39.77 - 62.46 |
| Volume | |
| Avg. volume | 2,059 |
| Market cap | 10.601B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 22.86 |
| EPS (TTM) | 1.74 |
| Earnings date | N/A |
| Forward dividend & yield | 0.86 (2.12%) |
| Ex-dividend date | 03 Mar 2023 |
| 1y target est | N/A |
Globe NewswireNovozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices. Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the lau
ZacksPPG or NVZMY: Which Is the Better Value Stock Right Now?
PPG vs. NVZMY: Which Stock Is the Better Value Option?
- Globe Newswire
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption. Copenhagen, Denmark – 4 September 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising prod
